Aurobindo Pharma announced that its subsidiary CuraTeQ Biologics Pvt Ltd. has expanded the scope of its marketing and distribution
agreement with Orion Corporation (Orion) to commercialize its biosimilars pipeline to include the Baltic states in Europe.
Earlier in 2020, CuraTeQ and Orion had entered into a licensing agreement, granting marketing and distribution rights for CuraTeQ’s biosimilar products under development in the Nordic states, Austria, Hungary and Slovenia
Aurobindo Pharma was quoting at Rs 720.65, down Rs 17.30, or 2.34 percent on the BSE.
News Source:- Moneycontrol